+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896742
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Cancer Drugs Market is projected to reach USD 4.49 Billion in 2026. It is expected to continue growing at a CAGR of 5.92%, reaching USD 6.36 Billion by 2032.

Primary liver cancer remains one of oncology’s highest-urgency treatment areas. According to IARC GLOBOCAN 2022, liver cancer accounted for approximately 866,000 new cases and 759,000 deaths worldwide, ranking among the leading causes of cancer mortality. Hepatocellular carcinoma represents the majority of cases, while cholangiocarcinoma and other rare liver malignancies add clinically complex, high-need segments.

The liver cancer drugs landscape is being reshaped by immune checkpoint inhibitors, anti-VEGF combinations, tyrosine kinase inhibitors, and biomarker-directed therapies. Demand is supported by high unmet need, chronic hepatitis B and C burden, rising metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and expanding use of systemic therapy in advanced hepatocellular carcinoma treatment.

Transformative Shifts in Liver Cancer Treatment

The treatment landscape has moved beyond single-agent sorafenib toward combination immunotherapy, targeted therapy sequencing, and multidisciplinary care. Atezolizumab plus bevacizumab and durvalumab plus tremelimumab have changed first-line standards for eligible unresectable hepatocellular carcinoma patients, while lenvatinib, regorafenib, cabozantinib, ramucirumab, and immunotherapy options continue to support later-line strategies.

Commercial success increasingly depends on evidence generation across overall survival, progression-free survival, quality of life, safety in cirrhotic populations, biomarker selection, and real-world effectiveness. Drug developers are also expanding into adjuvant, neoadjuvant, locoregional-combination, and earlier-stage settings where recurrence risk after resection or ablation remains substantial.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across liver cancer drug discovery, clinical development, and care delivery. AI-enabled imaging analytics, radiomics, digital pathology, and electronic health record mining are being used to identify high-risk patients, refine trial eligibility, support earlier detection of disease progression, and evaluate treatment response more consistently.

For manufacturers, AI can improve target discovery, molecule screening, trial site selection, patient recruitment, adverse event monitoring, and real-world evidence generation. The greatest near-term impact is expected where AI tools are prospectively validated, integrated with clinician workflows, and aligned with regulatory expectations for transparency, bias control, data quality, and clinical utility.

Regional Insights Across the Liver Cancer Drugs Market

Asia-Pacific represents the largest epidemiological opportunity for liver cancer drugs because hepatitis B prevalence, population scale, and established regional disease burden drive substantial incidence, with China contributing a major share of global cases reported by IARC. Japan, South Korea, Australia, India, and ASEAN markets are expanding adoption of immunotherapy and targeted therapies, although reimbursement depth, screening coverage, and specialist access vary widely across public and private healthcare systems.

North America remains a high-value region due to broad access to FDA-approved systemic therapies, strong guideline adoption, advanced oncology infrastructure, and significant clinical trial activity. Europe benefits from EMA approvals, national health technology assessment systems, and mature liver disease networks, but reimbursement timing and evidence thresholds differ across major economies. Latin America shows growing demand in Brazil and Mexico, while affordability, diagnostic delays, and public-sector access remain constraints. The Middle East is investing in tertiary oncology centers, particularly across the GCC, and Africa faces the greatest access gap despite meaningful viral hepatitis, aflatoxin exposure, and late-stage disease burden.

Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is shaped by hepatitis B-related liver cancer, uneven screening coverage, variable reimbursement, and accelerating private-sector oncology investment in major urban centers. The GCC is characterized by rising specialist capacity, public healthcare investment, and demand for innovative oncology therapies, particularly as national cancer strategies strengthen diagnosis, referral pathways, and tertiary treatment access.

The European Union emphasizes comparative clinical benefit, budget impact, and health technology assessment discipline, making robust survival, safety, and quality-of-life evidence essential for liver cancer drug adoption. BRICS countries combine high patient volume, local manufacturing ambitions, and strong pricing pressure, creating opportunities for differentiated originators, biosimilars, generics, and access partnerships. G7 markets remain central to premium launch sequencing, guideline influence, and clinical trial leadership, while NATO member countries overlap with many advanced regulatory and supply-chain environments where resilience, pharmacovigilance, secure distribution, and continuity of oncology care are increasingly important.

Country Insights for Strategic Market Prioritization

The United States is a leading commercial environment for liver cancer drugs due to rapid FDA uptake, specialist networks, broad clinical trial activity, and established use of immunotherapy combinations in eligible patients. Canada offers structured provincial reimbursement and guideline-led adoption, while Mexico and Brazil present large patient pools with persistent access differences between private and public systems and rising demand for advanced hepatocellular carcinoma treatment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are important launch markets shaped by NICE, AMNOG, HAS, AIFA, and national reimbursement frameworks that scrutinize clinical benefit, safety, and economic value. Russia remains clinically relevant but is affected by procurement, access, and geopolitical complexity. China is critical because of its liver cancer burden, hepatitis B prevalence, expanding domestic oncology innovation, and growing use of immuno-oncology regimens. India combines high unmet need with affordability constraints and uneven specialist access, Japan and South Korea have advanced oncology adoption supported by strong hospital infrastructure, and Australia provides guideline-based access with a comparatively smaller population base.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated combination strategies, biomarker-informed development, and evidence packages that address cirrhosis, bleeding risk, liver function, viral etiology, and real-world tolerability. Trial designs should include globally representative populations, viral and non-viral etiologies, diverse liver function profiles, and endpoints that reflect both survival and patient experience.

Market access teams should build early health economic models, plan companion diagnostics where relevant, and pursue partnerships that improve screening, referral, treatment initiation, and continuity of care. Organizations competing in liver cancer drugs should also strengthen pharmacovigilance, physician education, patient support, and supply reliability across emerging markets where late diagnosis and access limitations remain major barriers.

Research Methodology

This executive summary is based on triangulated secondary and primary research. Core inputs include WHO and IARC GLOBOCAN cancer statistics, FDA and EMA approval records, ClinicalTrials.gov, peer-reviewed oncology journals, and treatment guidelines from organizations such as NCCN, ESMO, AASLD, and ASCO.

Market interpretation was developed by assessing epidemiology, therapy adoption, clinical trial pipelines, reimbursement environments, regulatory pathways, competitive positioning, and regional access dynamics. Findings were validated through cross-source comparison and expert interpretation to ensure that conclusions are evidence-based, commercially relevant, and suitable for strategic planning without relying on market sizing or forecasting.

Conclusion and Strategic Outlook

The liver cancer drugs landscape is entering a more competitive and evidence-intensive era. Immunotherapy combinations have raised the standard of care, targeted therapies continue to support sequencing strategies, and AI is strengthening discovery, trial execution, clinical workflow integration, and real-world evidence generation.

Sustained progress will depend on earlier diagnosis, broader access, rational combinations, biomarker development, and proof of value across diverse healthcare systems. Organizations that align scientific innovation with affordability, safety, and measurable patient outcomes will be best positioned to lead in hepatocellular carcinoma treatment and the broader liver cancer therapeutics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Cancer Drugs Market, by Therapy Type
7.1. Chemotherapy
7.2. Immunotherapy
7.3. Radiation Therapy
7.4. Targeted Therapy
8. Liver Cancer Drugs Market, by Cancer Type
8.1. Cholangiocarcinoma
8.2. Hepatoblastoma
8.3. Hepatocellular Carcinoma (HCC)
9. Liver Cancer Drugs Market, by Administration Route
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Liver Cancer Drugs Market, by Drug Class
10.1. Cytotoxic Agents
10.2. Monoclonal Antibodies
10.3. Tyrosine Kinase Inhibitors (TKIs)
11. Liver Cancer Drugs Market, by End User
11.1. Home Care
11.2. Hospital
11.3. Specialty Clinic
12. Liver Cancer Drugs Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Asia-Pacific Liver Cancer Drugs Market
14. Europe Liver Cancer Drugs Market
15. North America Liver Cancer Drugs Market
16. Latin America Liver Cancer Drugs Market
17. Africa Liver Cancer Drugs Market
18. Middle East Liver Cancer Drugs Market
19. NATO Liver Cancer Drugs Market
20. G7 Liver Cancer Drugs Market
21. BRICS Liver Cancer Drugs Market
22. European Union Liver Cancer Drugs Market
23. ASEAN Liver Cancer Drugs Market
24. GCC Liver Cancer Drugs Market
25. China Liver Cancer Drugs Market
26. United States Liver Cancer Drugs Market
27. Japan Liver Cancer Drugs Market
28. India Liver Cancer Drugs Market
29. Germany Liver Cancer Drugs Market
30. United Kingdom Liver Cancer Drugs Market
31. Australia Liver Cancer Drugs Market
32. France Liver Cancer Drugs Market
33. South Korea Liver Cancer Drugs Market
34. Italy Liver Cancer Drugs Market
35. Canada Liver Cancer Drugs Market
36. Russia Liver Cancer Drugs Market
37. Brazil Liver Cancer Drugs Market
38. Mexico Liver Cancer Drugs Market
39. Spain Liver Cancer Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. AbbVie Inc.
41.2. Agenus Inc.
41.3. Alnylam Pharmaceuticals, Inc.
41.4. Astellas Pharma Inc.
41.5. AstraZeneca PLC
41.6. Bayer AG
41.7. BeiGene, Ltd.
41.8. Bristol-Myers Squibb Company
41.9. C. H. Boehringer Sohn AG & Co. KG
41.10. Can-Fite BioPharma Ltd.
41.11. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
41.12. CStone Pharmaceuticals
41.13. Eisai Co., Ltd.
41.14. Eli Lilly and Company
41.15. Exelixis, Inc.
41.16. F. Hoffmann-La Roche Ltd.
41.17. Genfit S.A.
41.18. Gilead Sciences, Inc.
41.19. GlaxoSmithKline plc
41.20. Innovent Biologics, Inc.
41.21. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
41.22. Ipsen SA
41.23. Jiangsu Hengrui Medicine Co., Ltd.
41.24. Johnson & Johnson Services Inc.
41.25. Merck & Co., Inc.
41.26. Moderna, Inc.
41.27. Novartis AG
41.28. Pfizer Inc.
41.29. Sanofi SA
41.30. Takeda Pharmaceutical Company Limited
41.31. Vertex Pharmaceuticals Incorporated
41.32. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 80. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 81. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 83. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 101. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 102. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 103. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 104. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. NATO LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 115. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 116. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 117. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. G7 LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 122. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 123. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 124. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. BRICS LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 129. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 130. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 131. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 132. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 143. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 144. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 145. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. GCC LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 150. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 151. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 152. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 153. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 156. CHINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 157. CHINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 158. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 159. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 160. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. JAPAN LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 171. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 172. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 173. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. INDIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. INDIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 178. INDIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 179. INDIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 180. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. INDIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. GERMANY LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 184. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 185. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 186. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 187. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 188. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 192. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 195. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 198. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 199. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 200. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 201. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. FRANCE LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 206. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 207. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 208. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 213. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 214. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 215. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 216. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. ITALY LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 219. ITALY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 220. ITALY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 221. ITALY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 222. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 223. ITALY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. CANADA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 226. CANADA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 227. CANADA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 228. CANADA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 229. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. CANADA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. RUSSIA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 234. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 235. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 236. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 237. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. BRAZIL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 243. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. MEXICO LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 248. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 249. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 250. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 251. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 253. SPAIN LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 255. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 256. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 257. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Liver Cancer Drugs market report include:
  • AbbVie Inc.
  • Agenus Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Can-Fite BioPharma Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genfit S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.36 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Therapeutics - Global Strategic Business Report - Product Image

Liver Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Liver Cancer Drug Market Report 2026 - Product Image

Liver Cancer Drug Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From

About the Liver Cancer Drugs Market

The Liver Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat liver cancer. These drugs are used to reduce the size of tumors, reduce symptoms, and improve the quality of life for those affected by the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells. Immunotherapy is a type of drug that works by stimulating the body's own immune system to fight cancer. The Liver Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly developing new drugs and treatments to improve the quality of life for those affected by liver cancer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.